Microbot Medical (NASDAQ:MBOT) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Microbot Medical's stock has been given a sell (D-) rating by Weiss Ratings, indicating potential concerns regarding its performance.
• The company has a consensus rating of "Hold" and an average price target of $12.00, with mixed ratings from various analysts.
• Microbot Medical recently reported earnings of ($0.10) per share, missing expectations, and anticipates posting -0.71 earnings per share for the current year.

Microbot Medical (NASDAQ:MBOT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

MBOT has been the subject of several other research reports. Wall Street Zen upgraded Microbot Medical from a "sell" rating to a "hold" rating in a research note on Friday, October 3rd. HC Wainwright increased their target price on Microbot Medical from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, September 11th. Finally, Zacks Research lowered Microbot Medical from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Microbot Medical presently has a consensus rating of "Hold" and an average price target of $12.00.

Microbot Medical Stock Performance

NASDAQ:MBOT traded down $0.10 during trading hours on Wednesday, hitting $3.20. 562,898 shares of the company's stock traded hands, compared to its average volume of 3,562,421. The firm has a market cap of $168.68 million, a P/E ratio of -5.51 and a beta of 1.25. Microbot Medical has a twelve month low of $0.88 and a twelve month high of $4.67. The stock's fifty day moving average price is $3.36 and its two-hundred day moving average price is $2.71.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). On average, equities research analysts predict that Microbot Medical will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Microbot Medical

Institutional investors have recently made changes to their positions in the stock. U.S. Capital Wealth Advisors LLC acquired a new position in Microbot Medical during the second quarter valued at approximately $25,000. American Century Companies Inc. bought a new position in Microbot Medical in the second quarter worth approximately $32,000. Beacon Capital Management LLC increased its stake in Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 10,000 shares in the last quarter. Virtu Financial LLC bought a new position in Microbot Medical in the 1st quarter valued at about $42,000. Finally, XTX Topco Ltd bought a new position in Microbot Medical in the 2nd quarter valued at about $43,000. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.